{"id":67125,"date":"2026-06-02T20:07:31","date_gmt":"2026-06-02T12:07:31","guid":{"rendered":"https:\/\/flcube.com\/?p=67125"},"modified":"2026-06-02T20:07:31","modified_gmt":"2026-06-02T12:07:31","slug":"rallybio-to-merge-with-avenzo-therapeutics-in-215-million-deal-creating-pipeline-rich-entity-focused-on-chinese-origin-oncology-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67125","title":{"rendered":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Rallybio Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/RLYB:NASDAQ\">NASDAQ: RLYB<\/a>) announced a definitive agreement to acquire <strong>Avenzo Therapeutics, Inc.<\/strong> through a merger transaction, creating a combined entity that will operate under the name <strong>Avenzo Therapeutics, Inc.<\/strong> and trade on Nasdaq under the new ticker symbol <strong>&#8220;AVZO&#8221;<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-strategic-context\" class=\"wp-block-heading\">Transaction Structure &amp; Strategic Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Rallybio Corporation (NASDAQ: RLYB)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Avenzo Therapeutics, Inc.<\/td><\/tr><tr><td><strong>Post-Merger Entity<\/strong><\/td><td>Avenzo Therapeutics, Inc. (NASDAQ: AVZO)<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Q4 2026<\/td><\/tr><tr><td><strong>Strategic Context<\/strong><\/td><td>Rallybio&#8217;s second merger attempt following failed Candid transaction<\/td><\/tr><tr><td><strong>Financing Component<\/strong><\/td><td>$215 million committed by healthcare institutional investors and mutual funds<\/td><\/tr><tr><td><strong>Financing Timing<\/strong><\/td><td>Expected to close immediately prior to merger completion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-avenzo-s-pipeline-four-chinese-origin-oncology-assets\" class=\"wp-block-heading\">Avenzo&#8217;s Pipeline \u2013 Four Chinese-Origin Oncology Assets<\/h2>\n\n\n\n<h3 id=\"h-cdk-inhibitor-portfolio-from-allorion-therapeutics\" class=\"wp-block-heading\">CDK Inhibitor Portfolio (from Allorion Therapeutics)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ARTS-021\/AVZO-021<\/strong>: Selective cyclin-dependent kinase 2 (CDK2) inhibitor<\/li>\n\n\n\n<li><strong>AVZO-023<\/strong>: CDK4 inhibitor<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Targeted cell cycle inhibition for precision oncology applications<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-bispecific-antibody-drug-conjugates-adcs\" class=\"wp-block-heading\">Bispecific Antibody-Drug Conjugates (ADCs)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DB-1418\/AVZO-1418<\/strong>: EGFR\/HER3 bispecific ADC (from Duality Biologics)<\/li>\n\n\n\n<li><strong>AVZO-103<\/strong>: Nectin4\/TROP2 bispecific ADC (from Velavigo)<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Dual-targeting approach enhances tumor specificity and payload delivery<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-rationale\" class=\"wp-block-heading\">Market Context &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Chinese Innovation Trend<\/strong><\/td><td>Growing trend of US biotech companies acquiring\/developing Chinese-origin assets<\/td><\/tr><tr><td><strong>Pipeline Diversification<\/strong><\/td><td>Four distinct mechanisms across targeted therapy and next-generation ADC platforms<\/td><\/tr><tr><td><strong>Investor Confidence<\/strong><\/td><td>$215 million financing commitment from leading healthcare institutions validates asset quality<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>CDK2\/4 inhibitors and bispecific ADCs represent high-value modalities in current oncology development<\/td><\/tr><tr><td><strong>Risk Mitigation<\/strong><\/td><td>Diversified portfolio reduces dependency on single asset or mechanism<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-implications-amp-capital-strategy\" class=\"wp-block-heading\">Financial Implications &amp; Capital Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Substantial Capital Infusion<\/strong>: $215 million financing provides significant runway for clinical development<\/li>\n\n\n\n<li><strong>De-risked Development<\/strong>: Multiple assets at various stages enable portfolio optimization and milestone-driven capital allocation<\/li>\n\n\n\n<li><strong>Global Development Strategy<\/strong>: Leverages Chinese innovation with US regulatory and commercial expertise<\/li>\n\n\n\n<li><strong>Investor Consortium<\/strong>: Participation of mutual funds and institutional healthcare investors indicates strong market confidence<\/li>\n\n\n\n<li><strong>Post-Merger Valuation<\/strong>: Combined entity positioned for enhanced market capitalization based on pipeline breadth<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction represents a strategic pivot for Rallybio, which previously attempted a merger with Candid, and establishes Avenzo as a pipeline-rich entity with access to cutting-edge Chinese oncology innovation and substantial financial backing from sophisticated healthcare investors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the merger transaction, financing activities, and development plans. Actual results may differ due to risks including regulatory approvals, transaction completion, and clinical development outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1721,4768,4638,4637],"class_list":["post-67125","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-avenzo-therapeutics","tag-nasdaq-avzo","tag-nasdaq-rlyb","tag-rallybio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol &quot;AVZO&quot;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67125\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets\" \/>\n<meta property=\"og:description\" content=\"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol &quot;AVZO&quot;.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67125\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T12:07:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets\",\"datePublished\":\"2026-06-02T12:07:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Avenzo Therapeutics\",\"NASDAQ: AVZO\",\"NASDAQ:\u202fRLYB\",\"Rallybio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67125#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67125\",\"name\":\"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T12:07:31+00:00\",\"description\":\"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol \\\"AVZO\\\".\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67125\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67125#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets - Insight, China&#039;s Pharmaceutical Industry","description":"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol \"AVZO\".","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67125","og_locale":"en_US","og_type":"article","og_title":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets","og_description":"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol \"AVZO\".","og_url":"https:\/\/flcube.com\/?p=67125","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T12:07:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67125#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67125"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets","datePublished":"2026-06-02T12:07:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67125"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Avenzo Therapeutics","NASDAQ: AVZO","NASDAQ:\u202fRLYB","Rallybio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67125#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67125","url":"https:\/\/flcube.com\/?p=67125","name":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T12:07:31+00:00","description":"Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a merger transaction, creating a combined entity that will operate under the name Avenzo Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol \"AVZO\".","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67125#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67125"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67125#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67125"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67125\/revisions"}],"predecessor-version":[{"id":67126,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67125\/revisions\/67126"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}